New Prevention Technologies
The 2010 discussion paper highlights the critical role of People Living with HIV (PLHIV) in the research and development of New Prevention Technologies (NPTs) such as vaccines, microbicides, and PrEP. It outlines the objectives of supporting documentation of PLHIV experiences, promoting their involvement in NPT initiatives, and informing networks about ongoing developments. Key outcomes include establishing meaningful roles for PLHIV in prevention research discussions and collaboration between treatment and prevention advocates. The results aim to build a comprehensive advocacy agenda for PLHIV engagement in future clinical trials.
New Prevention Technologies
E N D
Presentation Transcript
New Prevention Technologies 20 July 2010, AIDS 2010 Ebony Johnsson
At LIVING 2008 Summit Discussion paper on “Positive Prevention”: • Recognition of current research on NPTs (vaccines, microbicides, PrEP, Tx for Px) • Recommendation to explore role of PLHIV in NPT research and development
NPT Working Group - 1 • Convened September 2009 • Objectives: • Support the process of documenting the experiences and perspectives of PLHIV on NPTs; • Highlight and advocate for opportunities for PLHIV to be involved in NPT R&D; • Inform regional and national PLHIV networks of developments in the NPT field.
6 Networks of PLHIV APN+ All-Ukrainian Network of PLHIV GNP+NA NEPHAK (Kenya) PozFem UK RedLa+ 4 Partner Organizations EATG ICW Global ITPC/ HIV Collaborative Fund TAC NPT Working Group – 2
Four Moderated and Structured Teleconferences Research site investigators Site staff People living with HIV
Key discussion points • Meaningful roles for PLHIV in discussions on HIV prevention research ethics • Meaningful roles for PLHIV in addressing questions on ARV-based prevention • Collaboration between treatment and prevention advocates to address ARV-based prevention • Defining the role(s) of PLHIV in HIV prevention trials
Outputs Discussion paper: • Exploration of the roles of PLHIV in Biomedical Prevention Research Toolkit for networks of PLHIV: • New Prevention Tools – What are they? • What is their relevance for PLHIV? Participation and advocacy: • WHO PrEP & ART for Prevention Consultations (November 2009) • International Microbicides Conference (May 2010)
Scientific Community IAVI IPM Advocacy Community AVAC GCM IRMA Follow-up: Face-to-Face ConsultationAmsterdam, 5-6 July NPT Working Group Members
Discussions Updates on current HIV prevention trials Open and constructive dialogue about implications of NPT R&D for PLHIV: - Vaccines - Microbicides (Vaginal and Rectal) - PrEP - ART for prevention
We are developing an advocacy agenda! • Teleconferences, online discussions and face-to-face consultation will inform our advocacy agenda • Development and revision process: July 2010 – December 2010
Initial recommendations • Clarify range of Tx and Px linkages and implications for PLHIV • Develop guidance on ‘risk’ and ‘shared responsibility’ for PLHIV • Clarify target audiences of NPTs and plans for access at country-level • Map out what ‘meaningful engagement’ of PLHIV in clinical trials would look like • Develop clear guidelines for networks of PLHIV and normative agencies on representation in international consultations and meetings
Learn more! Poster presentation: 22 July 2010 12.30 – 14.30 Poster number: THPE0261
Thank you to the NPT Working Group and partners for supporting this programme!For more information, visit www.gnpplus.net